However, retrospective analyses of adverse event signals for HER-2 positive breast cancer TKIs remain scarce, particularly regarding their impact on different physiological systems and specific adverse event profiles (Harbeck et al., 2020). The gene discussed is ERBB2; the disease is breast carcinoma.